4-(2-(二乙基氨基)乙氧基)-苯胺 | 38519-63-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(2-(二乙基氨基)乙氧基)-苯胺
• 英文名称: 4-[2-(diethylamino)ethoxy]aniline
• 英文别名: 4-(2-diethylaminoethoxy)phenylamine；N,N-diethyl-2-(4-aminophenoxy)ethylamine
• CAS: 38519-63-0
• 化学式: C₁₂H₂₀N₂O
• mdl: MFCD05865149
• 分子量: 208.304
• InChiKey: LFJGGGIWERIGNX-UHFFFAOYSA-N

物化性质

• 沸点：
  170 °C(Press: 7 Torr)
• 密度：
  1.013±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922199090

SDS

Name:	4-[2-(Diethylamino)ethoxy]aniline Material Safety Data Sheet
Synonym:	4-(2-Diethylamino-ethoxy)-phenylamine
CAS:	38519-63-0

Section 1 - Chemical Product MSDS Name:4-[2-(Diethylamino)ethoxy]aniline Material Safety Data Sheet
Synonym:4-(2-Diethylamino-ethoxy)-phenylamine

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
38519-63-0	4-[2-(Diethylamino)ethoxy]aniline	97+	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 38519-63-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Oil
Color: colorless
Odor: slight
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 135-136 deg C @ 0.4mbar
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H20N2O
Molecular Weight: 208.30

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, acid chlorides, acids.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 38519-63-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-[2-(Diethylamino)ethoxy]aniline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
IMO
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
RID/ADR
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 23 Do not inhale gas/fumes/vapour/spray.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 38519-63-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 38519-63-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 38519-63-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(2-(二乙基氨基)乙氧基)-苯胺 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 N-(4-(2-(diethylamino)ethoxy)phenyl)-4-(piperidin-1-ylmethyl)benzene-sulfonamide
  参考文献：
  名称：

  苯磺酰胺类药物：一类独特的趋化因子受体 4 型抑制剂

  摘要：

  CXCR4 与 CXCL12 (SDF-1) 的相互作用通过促进肿瘤细胞归巢至转移部位而在癌症转移中发挥关键作用。基于我们之前发表的CXCR4拮抗剂工作，我们合成了一系列抑制CXCR4/CXCL12相互作用的芳基磺酰胺类药物。通过结合亲和力和基质胶侵袭测定评估类似物的生物活性。采用计算机建模来评估对接至 CXCR4 X 射线结构的新类似物的选择，并合理化亲和力与基质胶体外测定之间的差异。先导化合物在结合亲和力测定 (IC 50 =8.0 n M ) 和基质胶侵袭测定（10 n M时 100 % 阻断侵袭）中显示出纳摩尔效力。这些数据表明苯磺酰胺是一类独特的高效 CXCR4 抑制剂。

  DOI：

  10.1002/cmdc.201200582
• 作为产物：
  描述：

  N,N-二乙基氯乙胺 在 盐酸 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 生成 4-(2-(二乙基氨基)乙氧基)-苯胺
  参考文献：
  名称：

  苯磺酰胺类药物：一类独特的趋化因子受体 4 型抑制剂

  摘要：

  CXCR4 与 CXCL12 (SDF-1) 的相互作用通过促进肿瘤细胞归巢至转移部位而在癌症转移中发挥关键作用。基于我们之前发表的CXCR4拮抗剂工作，我们合成了一系列抑制CXCR4/CXCL12相互作用的芳基磺酰胺类药物。通过结合亲和力和基质胶侵袭测定评估类似物的生物活性。采用计算机建模来评估对接至 CXCR4 X 射线结构的新类似物的选择，并合理化亲和力与基质胶体外测定之间的差异。先导化合物在结合亲和力测定 (IC 50 =8.0 n M ) 和基质胶侵袭测定（10 n M时 100 % 阻断侵袭）中显示出纳摩尔效力。这些数据表明苯磺酰胺是一类独特的高效 CXCR4 抑制剂。

  DOI：

  10.1002/cmdc.201200582
• 作为试剂：
  描述：

  4-[2-(吡咯烷-1-基)乙氧基]苯胺 、 2-二乙氨基氯乙烷盐酸盐 在 4-(2-(二乙基氨基)乙氧基)-苯胺 、 crude material 、 silica gel 、 methanol-dichloromethane 作用下， 反应 1.0h， 生成 4-(2-(二乙基氨基)乙氧基)-苯胺
  参考文献：
  名称：

  Thiazole and pyrazole derivatives as flt-3 kinase inhibitors

  摘要：

  本发明涉及式(I)的噻唑和吡唑衍生物，其中Q为S且X为C，或者Q为CH且X为N；R1为未取代或取代的苯基；R2为未取代或取代的芳基或杂环基；或者上述化合物的盐，以及制备这些化合物的方法，包括含有这些衍生物的药物组合物，以及使用这些衍生物制备用于治疗增殖性疾病的药物组合物，如肿瘤疾病，特别是对抑制Flt-3激酶有反应的这种疾病。

  公开号：

  US20070167449A1

文献信息

• [EN] PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE<br/>[FR] DÉRIVÉ DE PYRIMIDO-PYRIMIDO-INDAZOLE
  申请人：BANYU PHARMA CO LTD

  公开号：WO2010098367A1

  公开（公告）日：2010-09-02

  The invention is to provide a novel anticancer agent or sensitizer for cancer chemotherapy or radiotherapy. A compound of a general formula (I): wherein A means an aryl group or a heteroaryl group, or a group of a formula (a):; R1 means a -(C=O)aOb(C1-C6)alkyl group, a -(C=O)aOb(C2-C6)alkenyl group, a -(C=O)aOb(C3-C6)cycloalkyl group, an aryl group or a heteroaryl group; R2 and R3 each mean a hydrogen atom, a halogen atom, a hydroxyl group, a carboxyl group, a -(C=O)aOb(C1-C6)alkyl group or a group of -(C=O)aN(R1e)R2e; R4 means a hydrogen atom or a (C1-C6)alkyl group, and the like have an excellent Wee1-kinase-inhibitory effect, and are therefore useful in the field of medicine, especially in the field of various cancer treatments.

  这项发明是为了提供一种新型的抗癌药物或增敏剂，用于癌症化疗或放疗。通式(I)的化合物：其中A表示芳基或杂环基，或者是式(a)的基团；R1表示-(C=O)aOb(C1-C6)烷基、-(C=O)aOb(C2-C6)烯基、-(C=O)aOb(C3-C6)环烷基、芳基或杂环基；R2和R3各自表示氢原子、卤素原子、羟基、羧基、-(C=O)aOb(C1-C6)烷基或-(C=O)aN(R1e)R2e的基团；R4表示氢原子或(C1-C6)烷基等，具有优异的Wee1激酶抑制作用，因此在医学领域特别是各种癌症治疗领域中非常有用。
• Design, synthesis, and biological evaluation of pyrimidine-2-carboxamide analogs: investigation for novel RAGE inhibitors with reduced hydrophobicity and toxicity
  作者：Seok-Ho Kim、Young Taek Han

  DOI：10.1007/s12272-015-0596-5

  日期：2015.11

  This paper describes an investigation of novel RAGE inhibitors with improved drug-like properties. To identify the improved drug-like RAGE inhibitor, we designed and synthesized pyrimidine-2-carboxamide analogs based on our previous work. Several potent analogs with improved hydrophilicity were identified by evaluation of RAGE inhibitory activity. In particular, one of the potent (diethylamino)ethoxymethoxy analogs did not exhibit undesired cytotoxicity in contrast with the parent RAGE inhibitors.

  本论文描述了一项关于新型RAGE抑制剂的研究，旨在提升其类药物性质。为了发现具有更佳类药物特性的RAGE抑制剂，我们基于先前的研究，设计并合成了吡啶-2-羧酰胺类似物。通过评估RAGE抑制活性，我们鉴定出了几种具有增强亲水性的强效类似物。特别是其中一种强效的双乙基氨基乙氧基甲氧基类似物，与原始的RAGE抑制剂相比，并未表现出不期望的细胞毒性。
• [EN] PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS<br/>[FR] INHIBITEURS DE PROTÉINE KINASE ET LEURS UTILISATIONS POUR LE TRAITEMENT DE MALADIES ET DE PROBLÈMES DE SANTÉ
  申请人：UNIV HOUSTON SYSTEM

  公开号：WO2020232190A1

  公开（公告）日：2020-11-19

  Identified compounds demonstrate protein kinase inhibitory activity. More specifically, the compounds are demonstrated to inhibit receptor interacting kinase 2 (RIPK2) and/or Activin-like kinase 2 (ALK2) and/or receptor interacting kinase 3 (RIPK3). Compounds that are either dual RIPK2/ALK2 inhibitors or that preferentially inhibit RIPK2 or ALK2 or RIPK3 could provide therapeutic benefit. Compounds that function as RIPK3 inhibitors provide therapeutic benefit in the treatment of inflammatory and degenerative conditions.

  已识别的化合物具有蛋白激酶抑制活性。更具体地说，这些化合物被证实可以抑制受体相互作用激酶2（RIPK2）和/或激活素样激酶2（ALK2）和/或受体相互作用激酶3（RIPK3）。既能作为RIPK2/ALK2双重抑制剂，或优先抑制RIPK2或ALK2或RIPK3的化合物，可能提供治疗益处。作为RIPK3抑制剂的化合物在治疗炎症和退行性病症方面提供治疗益处。
• Bicyclic nitrogen heterocycles
  申请人：Hoffmann-La Roche Inc.

  公开号：US06150373A1

  公开（公告）日：2000-11-21

  Amino-substituted dihydropyrimido[4,5-d]pyrimidinones of the formula in which R.sup.1 represents hydrogen, lower alkyl, aryl, aryl-lower alkyl, heteroaryl, heteroaryl-lower alkyl, lower cycloalkyl or lower cycloalkyl-lower alkyl, R.sup.2 represents lower alkyl, aryl, aryl-lower alkyl, heteroaryl, heteroaryl-lower alkyl, lower cycloalkyl or lower cycloalkyl-lower alkyl, and R.sup.3 represents hydrogen, lower alkyl, aryl, aryl-lower alkyl, heteroaryl, heteroaryl-lower alkyl, lower cycloalkyl, lower cycloalkenyl or lower cycloalkyl-lower alkyl, and pharmaceutically acceptable salts thereof are protein kinase inhibitors. They can be used in the treatment or prophylaxis of inflammatory, immunological, oncological, bronchopulmonary, dermatological and cardiovascular disorders, in the treatment of asthma, central nervous system disorders or diabetic complications or for the prevention of graft rejection following transplant surgery.

  氨基取代的二氢嘧啶[4,5-d]嘧啶酮的公式，其中R.sup.1代表氢，低级烷基，芳基，芳基-低级烷基，杂芳基，杂芳基-低级烷基，低级环烷基或低级环烷基-低级烷基，R.sup.2代表低级烷基，芳基，芳基-低级烷基，杂芳基，杂芳基-低级烷基，低级环烷基或低级环烷基-低级烷基，R.sup.3代表氢，低级烷基，芳基，芳基-低级烷基，杂芳基，杂芳基-低级烷基，低级环烷基，低级环烯基或低级环烷基-低级烷基，以及药用可接受的盐，它们是蛋白激酶抑制剂。它们可用于治疗或预防炎症、免疫、肿瘤、支气管肺、皮肤和心血管疾病，在治疗哮喘、中枢神经系统疾病或糖尿病并发症，或用于预防移植手术后的移植物排斥反应。
• 2-Substituted Aminopyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-ones. Structure−Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity
  作者：Sylvester R. Klutchko、James M. Hamby、Diane H. Boschelli、Zhipei Wu、Alan J. Kraker、Aneesa M. Amar、Brian G. Hartl、Cynthia Shen、Wayne D. Klohs、Randall W. Steinkampf、Denise L. Driscoll、James M. Nelson、William L. Elliott、Billy J. Roberts、Chad L. Stoner、Patrick W. Vincent、Donald J. Dykes、Robert L. Panek、Gina H. Lu、Terry C. Major、Tawny K. Dahring、Hussein Hallak、Laura A. Bradford、H. D. Hollis Showalter、Annette M. Doherty

  DOI：10.1021/jm9802259

  日期：1998.8.1

  engaged in therapeutic intervention against a number of proliferative diseases, we have discovered the 2-aminopyrido[2, 3-d]pyrimidin-7(8H)-ones as a novel class of potent, broadly active tyrosine kinase (TK) inhibitors. An efficient route was developed that enabled the synthesis of a wide variety of analogues with substitution on several positions of the template. From the lead structure 2, a series

  在从事针对许多增生性疾病的治疗干预时，我们发现了2-氨基吡啶并[2,3-d]嘧啶7（8H）-一类新型有效的，广泛活性的酪氨酸激酶（TK）抑制剂。开发了一种有效的途径，该途径使得能够合成多种类似物，并在模板的多个位置上进行取代。由铅结构2，制得一系列在C-2位带有可变取代基和在N-8位带有甲基或乙基的类似物。该系列化合物可与ATP竞争，并且对包括受体（血小板衍生的生长因子，PDGFr，成纤维细胞生长因子，FGFr，表皮生长因子，EGFr）和非受体（c-Src）在内的一系列TK表现出亚微摩尔至低纳摩尔的效能）类。评估更充分的成员之一是63，IC50值分别为0.079 microM（PDGFr），0.043 microM（bFGFr），0.044 microM（EGFr）和0.009 microM（c-Src）。在细胞研究中，许多细胞系中有63种抑制PDGF介导的受体自身磷酸化，IC5​​0值为0